

The present invention relates to stabilised pharmaceutical compositions with an amorphous form of l-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methyl-piperidine (donepezil) hydrochloride and to a process for the stabilisation of this compound. The pharmaceutical composition is prepared by in situ formation of donepezil hydrochloride and loading the obtained solution onto a mixture of pharmaceutically acceptable excipients. The amorphous form of donepezil hydrochloride is stabilised by adding a crystallization inhibitor to the solution or to the mixture of pharmaceutically acceptable excipients.